Literature DB >> 27687020

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

D E Gladstone1, M Petri1, J Bolaños-Meade1, A E Dezern1, R J Jones1, D Fine1, R A Brodsky1.   

Abstract

Systemic lupus erythematosus (SLE), a disorder of the immune system, is potentially curable by allogeneic bone marrow transplantation (alloBMT). Until recently, alloBMT was limited by donor availability and toxicity. Reduced intensity conditioning (RIC) combined with post-transplantation cyclophosphamide (PTCy) has improved the availability and safety of alloBMT permitting its exploration in severe-refractory autoimmune illnesses. We report the six-year follow-up of a young female whose refractory SLE-associated nephrosis resolved after RIC alloBMT with PTCy.

Entities:  

Keywords:  Systemic lupus erythematosus; alloBMT

Mesh：

Substances：

Year:  2016        PMID： 27687020      PMCID： PMC5374037          DOI： 10.1177/0961203316669242

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


  16 in total

Review 1.  Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Authors:  Satkiran S Grewal; Juliet N Barker; Stella M Davies; John E Wagner
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

2.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

3.  Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation.

Authors:  Shigeo Fuji; Fumiaki Nakamura; Kazuo Hatanaka; Shuichi Taniguchi; Maho Sato; Shin-Ichiro Mori; Hisashi Sakamaki; Hiromasa Yabe; Toshihiro Miyamoto; Heiwa Kanamori; Yasunori Ueda; Keisei Kawa; Koji Kato; Ritsuro Suzuki; Yoshiko Atsuta; Toshiharu Tamaki; Yoshinobu Kanda
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

4.  High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.

Authors:  Amy E DeZern; Michelle Petri; Daniel B Drachman; Doug Kerr; Edward R Hammond; Jeanne Kowalski; Hua-Ling Tsai; David M Loeb; Grant Anhalt; Fredrick Wigley; Richard J Jones; Robert A Brodsky
Journal:  Medicine (Baltimore)       Date:  2011-03       Impact factor: 1.889

5.  High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.

Authors:  Douglas E Gladstone; Kenneth W Zamkoff; Lauren Krupp; Robert Peyster; Patrick Sibony; Christopher Christodoulou; Emily Locher; Patricia K Coyle
Journal:  Arch Neurol       Date:  2006-08-14

6.  High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial.

Authors:  Michelle Petri; Robert A Brodsky; Richard J Jones; Douglas Gladstone; Michael Fillius; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2010-05

7.  Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells.

Authors:  M Kwon; C Martínez-Laperche; P Balsalobre; D Serrano; J Anguita; J Gayoso; J L Díez-Martín; I Buño
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

8.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

9.  Mixed donor chimerism in non-malignant haematological diseases after allogeneic bone marrow transplantation.

Authors:  Ghassan Umair Shamshad; Suhaib Ahmed; Farhat Abbas Bhatti; Nadir Ali
Journal:  J Coll Physicians Surg Pak       Date:  2012-12       Impact factor: 0.711

10.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742
View more
  1 in total

1.  Intrathecal Injection of Mesenchymal Stromal Cell Cultured on 3D Fiber Ameliorates Multiple Organ Damage in Murine Lupus.

Authors:  Yuki Saito; Maki Miyajima; Sena Yamamoto; Norihiro Miura; Tsukasa Sato; Arisa Kita; Shogo Ijima; Mineko Fujimiya; Takako S Chikenji
Journal:  Stem Cells Transl Med       Date:  2022-06-22       Impact factor: 7.655
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.